Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$47.86 - $75.05 $38.3 Million - $60 Million
799,664 New
799,664 $43.3 Million
Q4 2023

Feb 09, 2024

BUY
$26.88 - $83.49 $19.4 Million - $60.3 Million
722,229 New
722,229 $60.3 Million
Q3 2023

Nov 13, 2024

BUY
$29.46 - $36.61 $24.4 Million - $30.4 Million
829,507 New
829,507 $24.4 Million
Q3 2023

Nov 13, 2023

SELL
$29.46 - $36.61 $24.3 Million - $30.1 Million
-823,496 Closed
0 $0
Q2 2023

Aug 14, 2024

SELL
$32.62 - $40.75 $1.57 Million - $1.96 Million
-48,214 Reduced 6.03%
751,450 $24.5 Million
Q2 2023

Aug 14, 2023

SELL
$32.62 - $40.75 $24.6 Million - $30.7 Million
-752,734 Closed
0 $0
Q1 2023

May 15, 2024

BUY
$33.36 - $45.71 $24.6 Million - $33.7 Million
738,159 New
738,159 $26 Million
Q4 2022

Feb 14, 2023

BUY
$35.77 - $51.11 $30 Million - $42.9 Million
839,356 New
839,356 $38.5 Million
Q3 2022

Nov 13, 2023

BUY
$38.54 - $54.52 $31.7 Million - $44.9 Million
823,496 New
823,496 $39.9 Million
Q2 2022

Aug 14, 2023

BUY
$33.93 - $48.92 $25.5 Million - $36.8 Million
752,734 New
752,734 $29.6 Million
Q1 2022

May 12, 2023

SELL
$29.74 - $46.0 $7.23 Million - $11.2 Million
-242,977 Reduced 28.95%
596,379 $22 Million
Q4 2020

Feb 10, 2021

SELL
$15.26 - $28.61 $3.16 Million - $5.93 Million
-207,200 Closed
0 $0
Q3 2020

Nov 12, 2021

BUY
$20.58 - $28.96 $4.26 Million - $6 Million
207,200 New
207,200 $4.49 Million
Q3 2020

Nov 10, 2020

SELL
$20.58 - $28.96 $4.26 Million - $6 Million
-207,200 Closed
0 $0
Q2 2020

Aug 13, 2021

BUY
$11.15 - $24.64 $2.31 Million - $5.11 Million
207,200 New
207,200 $4.88 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.69B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.